Akero Therapeutics (NASDAQ:AKRO) Director Aaron Royston Buys 67,829 Shares

Akero Therapeutics (NASDAQ:AKRO) Director Aaron Royston purchased 67,829 shares of Akero Therapeutics stock in a transaction dated Friday, June 21st. The stock was bought at an average cost of $2.50 per share, with a total value of $169,572.50.

AKRO stock traded down $3.57 during trading hours on Monday, hitting $22.37. 96,340 shares of the stock traded hands, compared to its average volume of 98,099. The firm has a 50-day moving average of $26.12. Akero Therapeutics has a one year low of $16.06 and a one year high of $30.30.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Monday, August 12th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($1.85). Sell-side analysts expect that Akero Therapeutics will post -2.72 EPS for the current year.

Several research analysts have recently issued reports on the stock. Roth Capital began coverage on shares of Akero Therapeutics in a report on Monday, July 15th. They issued a “buy” rating and a $34.00 price objective for the company. JPMorgan Chase & Co. started coverage on Akero Therapeutics in a report on Monday, July 15th. They set an “overweight” rating and a $28.00 target price on the stock. Evercore ISI assumed coverage on Akero Therapeutics in a research report on Monday, July 15th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Jefferies Financial Group started coverage on Akero Therapeutics in a research note on Monday, July 15th. They set a “buy” rating and a $28.00 price target for the company.

Several large investors have recently bought and sold shares of the company. Griffin Asset Management Inc. acquired a new stake in shares of Akero Therapeutics during the second quarter worth approximately $25,000. Tower Research Capital LLC TRC acquired a new stake in Akero Therapeutics during the 2nd quarter worth $26,000. Victory Capital Management Inc. bought a new stake in shares of Akero Therapeutics during the 2nd quarter valued at $31,000. Tiverton Asset Management LLC bought a new stake in shares of Akero Therapeutics during the 2nd quarter valued at $54,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Akero Therapeutics during the 2nd quarter valued at $77,000. Institutional investors own 37.34% of the company’s stock.

About Akero Therapeutics

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Featured Story: Certificate of Deposit (CD)

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.